BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

VentiRx Pharmaceuticals, Inc. 

1191 Second Avenue
Suite 1105
Seattle  Washington  98101  U.S.A.
Phone: 206-689-2259 Fax: n/a


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
VentiRx Pharmaceuticals, Inc. Announces The Completion Of Patient Enrollment In Randomized, Placebo-Controlled Phase 2 Trial Of VTX-2337 In Combination With Pegylated-Liposomal Doxorubicin In Platinum-Resistant Ovarian Cancer 4/17/2014 12:08:52 PM    More...
VentiRx Pharmaceuticals, Inc. Presents Phase 1 Data On VTX-2337 At 2014 Multidisciplinary Head And Neck Cancer Symposia 2/20/2014 9:48:38 AM    More...
VentiRx Pharmaceuticals, Inc. Initiates the ACTIVE8 Phase 2 Clinical Trial Evaluating VTX-2337 in Combination With Cetuximab and Chemotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 7/2/2013 9:55:06 AM    More...
VentiRx Pharmaceuticals, Inc. Release: Preclinical and Phase 1 Data of VTX-2337 Presented at 2013 American Society of Clinical Oncology Annual Meeting Shows Early Activity in Ovarian Cancer 6/3/2013 8:24:43 AM    More...
VentiRx Pharmaceuticals, Inc. Appoints James Kyle Bryan, M.D. as Chief Medical Officer 4/23/2013 7:38:54 AM    More...
VentiRx Pharmaceuticals, Inc. Initiates Randomized, Placebo-Controlled, Phase 2 Trial of VTX-2337 in Patients With Recurrent or Persistent Ovarian Cancer 10/22/2012 9:49:19 AM    More...
Celgene Corporation (CELG) Puts $35 Million Into VentiRx Pharmaceuticals, Inc., Gets Option to Buy Cancer Drugmaker 10/3/2012 6:45:23 AM    More...
VentiRx Pharmaceuticals, Inc. Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer 1/23/2012 10:22:46 AM    More...
VentiRx Pharmaceuticals, Inc. Concentrates on Cancer Development to Conserve Cash 9/14/2011 8:34:23 AM    More...
VentiRx Pharmaceuticals, Inc. Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 10/7/2010 7:30:54 AM    More...
12